Retour

RxSight, Inc. Announces Pricing of Public Offering of Common Stock

Stocks Changes in company's own shares

ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by RxSight. Before deducting the underwriting discount and estimated offering expenses payable by RxSight, RxSight expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 13, 2024, subject to satisfaction of customary closing conditions. BofA Securities is acting as lead bookrunning manager of the offering and as representative of the underwriters. J.P. Morgan is also acting as bookrunning manager for the offering. BTIG is acting as co-manager of the offering.

GlobeNewswire Inc. • 09/05/2024 à 03:15:00
RxSight, Inc. Common Stock
Address: 100 COLUMBIA STREET
Postal Code: 92656
City: ALISO VIEJO
State: CA
Phone Number: 949-521-7822
Website: https://www.rxsight.com
Status: Active
Company Info

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

List Date2021-07-30
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001111485
Composite figiBBG00THX1YN4
Share Class figiBBG00THX1YQ1
Market Cap2,380,507,042 USD
SIC Code3851
SIC DescriptionOPHTHALMIC GOODS
Total Employees374
Share Class Shares Outstanding38980000
Weighted Shares Outstanding39249910
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
60.441
62.28
64.275
60.259
58.79
Variance
-2.95%
-3.1%
6.75%
2.5%
-0.88%
Open
62.28
64.275
60.21
58.79
59.31
Highest
62.364
64.275
65.315
61.344
63.025
Lowest
62.28
64.275
64.47
61.242
63.021
History
PeriodVarhighestlowest
1 week
1.91%
63.025
61.242
1 month
18.25%
55.055
52.071
3 month
11.41%
56.22
24.662
6 month
11.41%
56.22
24.662
1 year
11.41%
56.22
24.662
3 year
11.41%
56.22
24.662
5 year
11.41%
56.22
24.662
10 year
11.41%
56.22
24.662
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-07 2023-11-09 UNPUB
Assets 202,532,000 195,261,000 181,850,000 UNPUB
Current Assets 187,666,000 180,445,000 167,947,000 UNPUB
Current Liabilities 14,876,000 16,565,000 18,942,000 UNPUB
Equity 145,009,000 157,188,000 161,479,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 145,009,000 157,188,000 161,479,000 UNPUB
Liabilities 57,523,000 38,073,000 20,371,000 UNPUB
Liabilities And Equity 202,532,000 195,261,000 181,850,000 UNPUB
Noncurrent Assets 14,866,000 14,816,000 13,903,000 UNPUB
Noncurrent Liabilities 42,647,000 21,508,000 1,429,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-07 2023-11-09 UNPUB
Exchange Gains/Losses 2,000 1,000 -5,000 UNPUB
Net Cash Flow -822,000 -2,259,000 1,054,000 UNPUB
Net Cash Flow, Continuing -824,000 -2,260,000 1,059,000 UNPUB
Net Cash Flow From Financing Activities 65,305,000 891,000 -8,234,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 65,305,000 891,000 -8,234,000 UNPUB
Net Cash Flow From Investing Activities -48,365,000 4,395,000 17,275,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -48,365,000 4,395,000 17,275,000 UNPUB
Net Cash Flow From Operating Activities -17,764,000 -7,546,000 -7,982,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -17,764,000 -7,546,000 -7,982,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-07 2023-11-09 UNPUB
Comprehensive Income/Loss -13,126,000 -13,868,000 -12,402,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -13,126,000 -13,868,000 -12,402,000 UNPUB
Other Comprehensive Income/Loss 86,000 -13,868,000 -12,402,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent 86,000 -64,000 13,000 UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-07 2023-11-09 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 30,701,000 34,588,000 34,602,000 UNPUB
Cost Of Revenue 7,123,000 8,795,000 8,468,000 UNPUB
Costs And Expenses 30,701,000 34,588,000 34,602,000 UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit 10,366,000 12,015,000 13,731,000 UNPUB
Income/Loss From Continuing Operations After Tax -13,212,000 -13,804,000 -12,415,000 UNPUB
Income/Loss From Continuing Operations Before Tax -13,212,000 -13,778,000 -12,403,000 UNPUB
Income Tax Expense/Benefit 0 26,000 12,000 UNPUB
Interest Expense, Operating 1,507,000 1,568,000 230,000 UNPUB
Net Income/Loss -13,212,000 -13,804,000 -12,415,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -13,212,000 -13,804,000 -12,415,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -13,212,000 -13,804,000 -12,415,000 UNPUB
Operating Expenses 23,463,000 25,640,000 26,243,000 UNPUB
Operating Income/Loss -13,097,000 -13,625,000 -12,512,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 17,489,000 20,810,000 22,199,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-08 2022-11-07 2023-03-06
Assets UNPUB 166,714,000 155,706,000 150,164,000
Current Assets UNPUB 149,928,000 139,162,000 134,555,000
Current Liabilities UNPUB 12,996,000 16,368,000 17,237,000
Equity UNPUB 109,986,000 95,959,000 89,902,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB 109,986,000 95,959,000 89,902,000
Liabilities UNPUB 56,728,000 59,747,000 60,262,000
Liabilities And Equity UNPUB 166,714,000 155,706,000 150,164,000
Noncurrent Assets UNPUB 16,786,000 16,544,000 15,609,000
Noncurrent Liabilities UNPUB 0 43,379,000 43,025,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-08 2022-11-07 2023-03-06
Exchange Gains/Losses UNPUB UNPUB -9,000 -9,000
Net Cash Flow UNPUB UNPUB -15,092,000 -12,577,000
Net Cash Flow, Continuing UNPUB UNPUB -15,083,000 -12,568,000
Net Cash Flow From Financing Activities UNPUB UNPUB -455,000 6,332,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB -455,000 6,332,000
Net Cash Flow From Investing Activities UNPUB UNPUB 560,000 39,950,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB 560,000 39,950,000
Net Cash Flow From Operating Activities UNPUB UNPUB -15,188,000 -58,850,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -15,188,000 -58,850,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-08 2022-11-07 2023-03-06
Comprehensive Income/Loss UNPUB -16,732,000 -16,773,000 -66,831,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -16,817,000 -16,773,000 -66,831,000
Other Comprehensive Income/Loss UNPUB 0 -16,773,000 -75,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB -85,000 45,000 -75,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-08 2022-11-07 2023-03-06
Basic Earnings Per Share UNPUB -1 -1 -2
Benefits Costs and Expenses UNPUB 28,092,000 29,433,000 115,752,000
Cost Of Revenue UNPUB 6,572,000 7,259,000 27,677,000
Costs And Expenses UNPUB 28,092,000 29,433,000 115,752,000
Diluted Earnings Per Share UNPUB -1 -1 -2
Gross Profit UNPUB 4,788,000 5,356,000 21,328,000
Income/Loss From Continuing Operations After Tax UNPUB -16,732,000 -16,818,000 -66,756,000
Income/Loss From Continuing Operations Before Tax UNPUB -16,732,000 -16,818,000 -66,747,000
Income Tax Expense/Benefit UNPUB 0 0 9,000
Interest Expense, Operating UNPUB 1,136,000 1,299,000 4,946,000
Net Income/Loss UNPUB -16,732,000 -16,818,000 -66,756,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -16,732,000 -16,818,000 -66,756,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -16,732,000 -16,818,000 -66,756,000
Operating Expenses UNPUB 20,580,000 21,314,000 84,646,000
Operating Income/Loss UNPUB -15,792,000 -15,958,000 -63,318,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 0
Revenues UNPUB 11,360,000 12,615,000 49,005,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-10 2022-03-08
Assets UNPUB UNPUB 203,736,000 192,721,000
Current Assets UNPUB UNPUB 186,336,000 176,295,000
Current Liabilities UNPUB UNPUB 9,176,000 11,077,000
Equity UNPUB UNPUB 150,891,000 138,242,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 150,891,000 138,242,000
Liabilities UNPUB UNPUB 52,845,000 54,479,000
Liabilities And Equity UNPUB UNPUB 203,736,000 192,721,000
Noncurrent Assets UNPUB UNPUB 17,400,000 16,426,000
Noncurrent Liabilities UNPUB UNPUB 43,669,000 43,402,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-10 2022-03-08
Exchange Gains/Losses UNPUB UNPUB -4,000 -10,000
Net Cash Flow UNPUB UNPUB 119,669,000 10,717,000
Net Cash Flow, Continuing UNPUB UNPUB 119,673,000 10,727,000
Net Cash Flow From Financing Activities UNPUB UNPUB 120,547,000 137,342,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 120,547,000 137,342,000
Net Cash Flow From Investing Activities UNPUB UNPUB 12,881,000 -81,907,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB 12,881,000 -81,907,000
Net Cash Flow From Operating Activities UNPUB UNPUB -13,755,000 -44,708,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -13,755,000 -44,708,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-10 2022-03-08
Comprehensive Income/Loss UNPUB UNPUB -12,681,000 -48,705,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -12,681,000 -48,705,000
Other Comprehensive Income/Loss UNPUB UNPUB -12,681,000 -17,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -8,000 -17,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-10 2022-03-08
Basic Earnings Per Share UNPUB UNPUB -1 -4
Benefits Costs and Expenses UNPUB UNPUB 18,463,000 71,273,000
Cost Of Revenue UNPUB UNPUB 4,445,000 18,076,000
Costs And Expenses UNPUB UNPUB 18,463,000 71,273,000
Diluted Earnings Per Share UNPUB UNPUB -1 -4
Gross Profit UNPUB UNPUB 1,341,000 4,517,000
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -12,673,000 -48,688,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -12,677,000 -48,680,000
Income Tax Expense/Benefit UNPUB UNPUB -4,000 8,000
Interest Expense, Operating UNPUB UNPUB 1,079,000 3,682,000
Net Income/Loss UNPUB UNPUB -12,673,000 -48,688,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -12,673,000 -48,688,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -12,673,000 -48,688,000
Operating Expenses UNPUB UNPUB 14,453,000 57,304,000
Operating Income/Loss UNPUB UNPUB -13,112,000 -52,787,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB 5,786,000 22,593,000
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:RXST240517P00075000 OPASPS Put American 100 75 BATO 2024-05-17
O:RXST240517P00070000 OPASPS Put American 100 70 BATO 2024-05-17
O:RXST240517P00065000 OPASPS Put American 100 65 BATO 2024-05-17
O:RXST240517P00060000 OPASPS Put American 100 60 BATO 2024-05-17
O:RXST240517P00055000 OPASPS Put American 100 55 BATO 2024-05-17
O:RXST240517P00050000 OPASPS Put American 100 50 BATO 2024-05-17
O:RXST240517P00045000 OPASPS Put American 100 45 BATO 2024-05-17
O:RXST240517P00040000 OPASPS Put American 100 40 BATO 2024-05-17
O:RXST240517P00035000 OPASPS Put American 100 35 BATO 2024-05-17
O:RXST240517P00030000 OPASPS Put American 100 30 BATO 2024-05-17
O:RXST240517P00025000 OPASPS Put American 100 25 BATO 2024-05-17
O:RXST240517C00075000 OCASPS Call American 100 75 BATO 2024-05-17
O:RXST240517C00070000 OCASPS Call American 100 70 BATO 2024-05-17
O:RXST240517C00065000 OCASPS Call American 100 65 BATO 2024-05-17
O:RXST240517C00060000 OCASPS Call American 100 60 BATO 2024-05-17
O:RXST240517C00055000 OCASPS Call American 100 55 BATO 2024-05-17
O:RXST240517C00050000 OCASPS Call American 100 50 BATO 2024-05-17
O:RXST240517C00045000 OCASPS Call American 100 45 BATO 2024-05-17
O:RXST240517C00040000 OCASPS Call American 100 40 BATO 2024-05-17
O:RXST240517C00035000 OCASPS Call American 100 35 BATO 2024-05-17
O:RXST240517C00030000 OCASPS Call American 100 30 BATO 2024-05-17
O:RXST240517C00025000 OCASPS Call American 100 25 BATO 2024-05-17
O:RXST240419P00075000 OPASPS Put American 100 75 BATO 2024-04-19
O:RXST240419P00070000 OPASPS Put American 100 70 BATO 2024-04-19
O:RXST240419P00065000 OPASPS Put American 100 65 BATO 2024-04-19
O:RXST240419P00060000 OPASPS Put American 100 60 BATO 2024-04-19
O:RXST240419P00055000 OPASPS Put American 100 55 BATO 2024-04-19
O:RXST240419P00050000 OPASPS Put American 100 50 BATO 2024-04-19
O:RXST240419P00045000 OPASPS Put American 100 45 BATO 2024-04-19
O:RXST240419P00040000 OPASPS Put American 100 40 BATO 2024-04-19
O:RXST240419P00035000 OPASPS Put American 100 35 BATO 2024-04-19
O:RXST240419P00030000 OPASPS Put American 100 30 BATO 2024-04-19
O:RXST240419P00025000 OPASPS Put American 100 25 BATO 2024-04-19
O:RXST240419C00075000 OCASPS Call American 100 75 BATO 2024-04-19
O:RXST240419C00070000 OCASPS Call American 100 70 BATO 2024-04-19
O:RXST240419C00065000 OCASPS Call American 100 65 BATO 2024-04-19
O:RXST240419C00060000 OCASPS Call American 100 60 BATO 2024-04-19
O:RXST240419C00055000 OCASPS Call American 100 55 BATO 2024-04-19
O:RXST240419C00050000 OCASPS Call American 100 50 BATO 2024-04-19
O:RXST240419C00045000 OCASPS Call American 100 45 BATO 2024-04-19
O:RXST240419C00040000 OCASPS Call American 100 40 BATO 2024-04-19
O:RXST240419C00035000 OCASPS Call American 100 35 BATO 2024-04-19
O:RXST240419C00030000 OCASPS Call American 100 30 BATO 2024-04-19
O:RXST240419C00025000 OCASPS Call American 100 25 BATO 2024-04-19
O:RXST240419P00085000 OPASPS Put American 100 85 BATO 2024-04-19
O:RXST240419P00080000 OPASPS Put American 100 80 BATO 2024-04-19
O:RXST240419C00085000 OCASPS Call American 100 85 BATO 2024-04-19
O:RXST240419C00080000 OCASPS Call American 100 80 BATO 2024-04-19
O:RXST240315P00050000 OPASPS Put American 100 50 BATO 2024-03-15
O:RXST240315P00045000 OPASPS Put American 100 45 BATO 2024-03-15
O:RXST240315P00040000 OPASPS Put American 100 40 BATO 2024-03-15
O:RXST240315P00035000 OPASPS Put American 100 35 BATO 2024-03-15
O:RXST240315P00030000 OPASPS Put American 100 30 BATO 2024-03-15
O:RXST240315P00025000 OPASPS Put American 100 25 BATO 2024-03-15
O:RXST240315P00022500 OPASPS Put American 100 22.5 BATO 2024-03-15
O:RXST240315P00020000 OPASPS Put American 100 20 BATO 2024-03-15
O:RXST240315P00017500 OPASPS Put American 100 17.5 BATO 2024-03-15
O:RXST240315C00050000 OCASPS Call American 100 50 BATO 2024-03-15
O:RXST240315C00045000 OCASPS Call American 100 45 BATO 2024-03-15
O:RXST240315C00040000 OCASPS Call American 100 40 BATO 2024-03-15
O:RXST240315C00035000 OCASPS Call American 100 35 BATO 2024-03-15
O:RXST240315C00030000 OCASPS Call American 100 30 BATO 2024-03-15
O:RXST240315C00025000 OCASPS Call American 100 25 BATO 2024-03-15
O:RXST240315C00022500 OCASPS Call American 100 22.5 BATO 2024-03-15
O:RXST240315P00080000 OPASPS Put American 100 80 BATO 2024-03-15
O:RXST240315C00020000 OCASPS Call American 100 20 BATO 2024-03-15
O:RXST240315P00065000 OPASPS Put American 100 65 BATO 2024-03-15
O:RXST240315P00075000 OPASPS Put American 100 75 BATO 2024-03-15
O:RXST240315C00017500 OCASPS Call American 100 17.5 BATO 2024-03-15
O:RXST240315P00060000 OPASPS Put American 100 60 BATO 2024-03-15
O:RXST240315C00080000 OCASPS Call American 100 80 BATO 2024-03-15
O:RXST240315P00070000 OPASPS Put American 100 70 BATO 2024-03-15
O:RXST240315C00075000 OCASPS Call American 100 75 BATO 2024-03-15
O:RXST240315P00055000 OPASPS Put American 100 55 BATO 2024-03-15
O:RXST240315C00065000 OCASPS Call American 100 65 BATO 2024-03-15
O:RXST240315C00070000 OCASPS Call American 100 70 BATO 2024-03-15
O:RXST240315C00060000 OCASPS Call American 100 60 BATO 2024-03-15
O:RXST240315C00055000 OCASPS Call American 100 55 BATO 2024-03-15
O:RXST240315P00015000 OPASPS Put American 100 15 BATO 2024-03-15
O:RXST240315P00012500 OPASPS Put American 100 12.5 BATO 2024-03-15
O:RXST240315C00015000 OCASPS Call American 100 15 BATO 2024-03-15
O:RXST240315C00012500 OCASPS Call American 100 12.5 BATO 2024-03-15
O:RXST240216P00065000 OPASPS Put American 100 65 BATO 2024-02-16
O:RXST240216P00060000 OPASPS Put American 100 60 BATO 2024-02-16
O:RXST240216C00065000 OCASPS Call American 100 65 BATO 2024-02-16
O:RXST240216C00060000 OCASPS Call American 100 60 BATO 2024-02-16
O:RXST240216P00055000 OPASPS Put American 100 55 BATO 2024-02-16
O:RXST240216P00050000 OPASPS Put American 100 50 BATO 2024-02-16
O:RXST240216P00045000 OPASPS Put American 100 45 BATO 2024-02-16
O:RXST240216P00040000 OPASPS Put American 100 40 BATO 2024-02-16
O:RXST240216P00035000 OPASPS Put American 100 35 BATO 2024-02-16
O:RXST240216P00030000 OPASPS Put American 100 30 BATO 2024-02-16
O:RXST240216P00025000 OPASPS Put American 100 25 BATO 2024-02-16
O:RXST240216P00022500 OPASPS Put American 100 22.5 BATO 2024-02-16
O:RXST240216P00020000 OPASPS Put American 100 20 BATO 2024-02-16
O:RXST240216C00055000 OCASPS Call American 100 55 BATO 2024-02-16
O:RXST240216C00050000 OCASPS Call American 100 50 BATO 2024-02-16
O:RXST240216C00045000 OCASPS Call American 100 45 BATO 2024-02-16
O:RXST240216C00040000 OCASPS Call American 100 40 BATO 2024-02-16
O:RXST240216C00035000 OCASPS Call American 100 35 BATO 2024-02-16
O:RXST240216C00030000 OCASPS Call American 100 30 BATO 2024-02-16
O:RXST240216C00025000 OCASPS Call American 100 25 BATO 2024-02-16
O:RXST240216C00022500 OCASPS Call American 100 22.5 BATO 2024-02-16
O:RXST240216C00020000 OCASPS Call American 100 20 BATO 2024-02-16
O:RXST240119P00040000 OPASPS Put American 100 40 BATO 2024-01-19
O:RXST240119P00035000 OPASPS Put American 100 35 BATO 2024-01-19
O:RXST240119P00030000 OPASPS Put American 100 30 BATO 2024-01-19
O:RXST240119P00025000 OPASPS Put American 100 25 BATO 2024-01-19
O:RXST240119P00022500 OPASPS Put American 100 22.5 BATO 2024-01-19
O:RXST240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:RXST240119P00017500 OPASPS Put American 100 17.5 BATO 2024-01-19
O:RXST240119P00015000 OPASPS Put American 100 15 BATO 2024-01-19
O:RXST240119C00040000 OCASPS Call American 100 40 BATO 2024-01-19
O:RXST240119C00035000 OCASPS Call American 100 35 BATO 2024-01-19
O:RXST240119C00030000 OCASPS Call American 100 30 BATO 2024-01-19
O:RXST240119C00025000 OCASPS Call American 100 25 BATO 2024-01-19
O:RXST240119C00022500 OCASPS Call American 100 22.5 BATO 2024-01-19
O:RXST240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:RXST240119C00017500 OCASPS Call American 100 17.5 BATO 2024-01-19
O:RXST240119P00045000 OPASPS Put American 100 45 BATO 2024-01-19
O:RXST240119C00015000 OCASPS Call American 100 15 BATO 2024-01-19
O:RXST240119C00045000 OCASPS Call American 100 45 BATO 2024-01-19
O:RXST231215P00050000 OPASPS Put American 100 50 BATO 2023-12-15
O:RXST231215P00045000 OPASPS Put American 100 45 BATO 2023-12-15
O:RXST231215P00040000 OPASPS Put American 100 40 BATO 2023-12-15
O:RXST231215P00035000 OPASPS Put American 100 35 BATO 2023-12-15
O:RXST231215P00030000 OPASPS Put American 100 30 BATO 2023-12-15
O:RXST231215P00025000 OPASPS Put American 100 25 BATO 2023-12-15
O:RXST231215P00022500 OPASPS Put American 100 22.5 BATO 2023-12-15
O:RXST231215P00020000 OPASPS Put American 100 20 BATO 2023-12-15
O:RXST231215P00017500 OPASPS Put American 100 17.5 BATO 2023-12-15
O:RXST231215P00015000 OPASPS Put American 100 15 BATO 2023-12-15
O:RXST231215P00012500 OPASPS Put American 100 12.5 BATO 2023-12-15
O:RXST231215P00010000 OPASPS Put American 100 10 BATO 2023-12-15
O:RXST231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:RXST231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:RXST231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:RXST231215C00050000 OCASPS Call American 100 50 BATO 2023-12-15
O:RXST231215C00045000 OCASPS Call American 100 45 BATO 2023-12-15
O:RXST231215C00040000 OCASPS Call American 100 40 BATO 2023-12-15
O:RXST231215C00035000 OCASPS Call American 100 35 BATO 2023-12-15
O:RXST231215C00030000 OCASPS Call American 100 30 BATO 2023-12-15
O:RXST231215C00025000 OCASPS Call American 100 25 BATO 2023-12-15
O:RXST231215C00022500 OCASPS Call American 100 22.5 BATO 2023-12-15
O:RXST231215C00020000 OCASPS Call American 100 20 BATO 2023-12-15
O:RXST231215C00017500 OCASPS Call American 100 17.5 BATO 2023-12-15
O:RXST231215C00015000 OCASPS Call American 100 15 BATO 2023-12-15
O:RXST231215C00012500 OCASPS Call American 100 12.5 BATO 2023-12-15
O:RXST231215C00010000 OCASPS Call American 100 10 BATO 2023-12-15
O:RXST231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:RXST231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:RXST231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:RXST231117P00040000 OPASPS Put American 100 40 BATO 2023-11-17
O:RXST231117P00035000 OPASPS Put American 100 35 BATO 2023-11-17
O:RXST231117P00030000 OPASPS Put American 100 30 BATO 2023-11-17
O:RXST231117P00025000 OPASPS Put American 100 25 BATO 2023-11-17
O:RXST231117P00022500 OPASPS Put American 100 22.5 BATO 2023-11-17
O:RXST231117P00020000 OPASPS Put American 100 20 BATO 2023-11-17
O:RXST231117P00017500 OPASPS Put American 100 17.5 BATO 2023-11-17
O:RXST231117P00015000 OPASPS Put American 100 15 BATO 2023-11-17
O:RXST231117C00040000 OCASPS Call American 100 40 BATO 2023-11-17
O:RXST231117C00035000 OCASPS Call American 100 35 BATO 2023-11-17
O:RXST231117C00030000 OCASPS Call American 100 30 BATO 2023-11-17
O:RXST231117C00025000 OCASPS Call American 100 25 BATO 2023-11-17
O:RXST231117C00022500 OCASPS Call American 100 22.5 BATO 2023-11-17
O:RXST231117C00020000 OCASPS Call American 100 20 BATO 2023-11-17
O:RXST231117C00017500 OCASPS Call American 100 17.5 BATO 2023-11-17
O:RXST231117C00015000 OCASPS Call American 100 15 BATO 2023-11-17
O:RXST231020P00045000 OPASPS Put American 100 45 BATO 2023-10-20
O:RXST231020P00040000 OPASPS Put American 100 40 BATO 2023-10-20
O:RXST231020P00035000 OPASPS Put American 100 35 BATO 2023-10-20
O:RXST231020P00030000 OPASPS Put American 100 30 BATO 2023-10-20
O:RXST231020P00025000 OPASPS Put American 100 25 BATO 2023-10-20
O:RXST231020P00022500 OPASPS Put American 100 22.5 BATO 2023-10-20
O:RXST231020P00020000 OPASPS Put American 100 20 BATO 2023-10-20
O:RXST231020P00017500 OPASPS Put American 100 17.5 BATO 2023-10-20
O:RXST231020P00015000 OPASPS Put American 100 15 BATO 2023-10-20
O:RXST231020C00045000 OCASPS Call American 100 45 BATO 2023-10-20
O:RXST231020C00040000 OCASPS Call American 100 40 BATO 2023-10-20
O:RXST231020C00035000 OCASPS Call American 100 35 BATO 2023-10-20
O:RXST231020C00030000 OCASPS Call American 100 30 BATO 2023-10-20
O:RXST231020C00025000 OCASPS Call American 100 25 BATO 2023-10-20
O:RXST231020C00022500 OCASPS Call American 100 22.5 BATO 2023-10-20
O:RXST231020C00020000 OCASPS Call American 100 20 BATO 2023-10-20
O:RXST231020C00017500 OCASPS Call American 100 17.5 BATO 2023-10-20
O:RXST231020C00015000 OCASPS Call American 100 15 BATO 2023-10-20
O:RXST230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:RXST230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:RXST230915P00040000 OPASPS Put American 100 40 BATO 2023-09-15
O:RXST230915P00035000 OPASPS Put American 100 35 BATO 2023-09-15
O:RXST230915P00030000 OPASPS Put American 100 30 BATO 2023-09-15
O:RXST230915P00025000 OPASPS Put American 100 25 BATO 2023-09-15
O:RXST230915P00022500 OPASPS Put American 100 22.5 BATO 2023-09-15
O:RXST230915P00020000 OPASPS Put American 100 20 BATO 2023-09-15
O:RXST230915P00017500 OPASPS Put American 100 17.5 BATO 2023-09-15
O:RXST230915P00015000 OPASPS Put American 100 15 BATO 2023-09-15
O:RXST230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:RXST230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:RXST230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:RXST230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:RXST230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:RXST230915C00040000 OCASPS Call American 100 40 BATO 2023-09-15
O:RXST230915C00035000 OCASPS Call American 100 35 BATO 2023-09-15
O:RXST230915C00030000 OCASPS Call American 100 30 BATO 2023-09-15
O:RXST230915C00025000 OCASPS Call American 100 25 BATO 2023-09-15
O:RXST230915C00022500 OCASPS Call American 100 22.5 BATO 2023-09-15
O:RXST230915C00020000 OCASPS Call American 100 20 BATO 2023-09-15
O:RXST230915C00017500 OCASPS Call American 100 17.5 BATO 2023-09-15
O:RXST230915C00015000 OCASPS Call American 100 15 BATO 2023-09-15
O:RXST230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:RXST230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:RXST230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:RXST230818P00040000 OPASPS Put American 100 40 BATO 2023-08-18
O:RXST230818P00035000 OPASPS Put American 100 35 BATO 2023-08-18
O:RXST230818P00030000 OPASPS Put American 100 30 BATO 2023-08-18
O:RXST230818P00025000 OPASPS Put American 100 25 BATO 2023-08-18
O:RXST230818P00022500 OPASPS Put American 100 22.5 BATO 2023-08-18
O:RXST230818P00020000 OPASPS Put American 100 20 BATO 2023-08-18
O:RXST230818P00017500 OPASPS Put American 100 17.5 BATO 2023-08-18
O:RXST230818P00015000 OPASPS Put American 100 15 BATO 2023-08-18
O:RXST230818C00040000 OCASPS Call American 100 40 BATO 2023-08-18
O:RXST230818C00035000 OCASPS Call American 100 35 BATO 2023-08-18
O:RXST230818C00030000 OCASPS Call American 100 30 BATO 2023-08-18
O:RXST230818C00025000 OCASPS Call American 100 25 BATO 2023-08-18
O:RXST230818C00022500 OCASPS Call American 100 22.5 BATO 2023-08-18
O:RXST230818C00020000 OCASPS Call American 100 20 BATO 2023-08-18
O:RXST230818C00017500 OCASPS Call American 100 17.5 BATO 2023-08-18
O:RXST230818C00015000 OCASPS Call American 100 15 BATO 2023-08-18
O:RXST230818P00045000 OPASPS Put American 100 45 BATO 2023-08-18
O:RXST230818C00045000 OCASPS Call American 100 45 BATO 2023-08-18
News Stream
Stocks Financing Agreements
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase up to 267,857 additional shares. RxSight’s gross proceeds from the offering were $115.0 million, before deducting underwriting discounts and commissions and other offering expenses.
GlobeNewswire Inc. • 6d ago
Stocks Changes in company's own shares
RxSight, Inc. Announces Pricing of Public Offering of Common Stock
ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by RxSight. Before deducting the underwriting discount and estimated offering expenses payable by RxSight, RxSight expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 13, 2024, subject to satisfaction of customary closing conditions. BofA Securities is acting as lead bookrunning manager of the offering and as representative of the underwriters. J.P. Morgan is also acting as bookrunning manager for the offering. BTIG is acting as co-manager of the offering.
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
GlobeNewswire Inc. • 3w ago
Analyst Analyst Ratings
Assessing RxSight: Insights From 8 Financial Analysts
RxSight (NASDAQ:RXST) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 4 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 2 0 0 0 3M Ago 0 2 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $59.12, a high estimate of $64.00, and a low estimate of $50.00. This upward trend is evident, with the current average reflecting a 21.0% increase from the previous average price target of $48.86. Understanding Analyst Ratings: A Comprehensive Breakdown In examining recent analyst actions, we gain insights into how financial experts perceive RxSight. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Saxon Needham Maintains Buy $64.00 - Thomas Stephan Stifel Raises Buy $64.00 $54.00 Robbie Marcus JP Morgan Raises Overweight $62.00 $40.00 Steven Lichtman Oppenheimer Raises Outperform $61.00 $54.00 David Saxon Needham Raises Buy $64.00 $53.00 Thomas Stephan Stifel Raises Buy $54.00 $45.00 Steven Lichtman Oppenheimer Raises Outperform $54.00 $50.00 Steven Lichtman Oppenheimer Raises Outperform $50.00 $46.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to RxSight. This offers insight into ...Full story available on Benzinga.com
Benzinga • 1mo ago
Calendar Calendar of Events
RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
ALISO VIEJO, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
GlobeNewswire Inc. • 1mo ago
stocks Calendar of Events
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference
ALISO VIEJO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 34th Annual Oppenheimer Healthcare Conference.
GlobeNewswire Inc. • 2mo ago
Analyst Analyst Ratings
Forecasting The Future: 9 Analyst Projections For RxSight
9 analysts have expressed a variety of opinions on RxSight (NASDAQ:RXST) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 5 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 3 0 0 0 3M Ago 1 2 0 0 0 Analysts have recently evaluated RxSight and provided 12-month price targets. The average target is $47.44, accompanied by a high estimate of $64.00 and a low estimate of $36.00. Surpassing the previous average price target of $44.50, the current average has increased by 6.61%. Investigating Analyst Ratings: An Elaborate Study The perception of RxSight by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Saxon Needham Raises Buy $64.00 $53.00 Thomas Stephan Stifel Raises Buy $54.00 $45.00 Steven Lichtman Oppenheimer Raises Outperform $54.00 $50.00 Steven Lichtman Oppenheimer Raises Outperform $50.00 $46.00 David Saxon Needham Raises Buy $41.00 $35.00 Steven Lichtman Oppenheimer Raises Outperform $46.00 $38.00 Larry Biegelsen Wells Fargo Announces Overweight $42.00 - Thomas Stephan Stifel Announces Buy $40.00 - Patrick Wood Morgan Stanley Announces Overweight $36.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, ...Full story available on Benzinga.com
Benzinga • 2mo ago
Stocks Earnings Releases and Operating Results
RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
ALISO VIEJO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2023.
GlobeNewswire Inc. • 2mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT